| Dr Timothy John Dietrich, DO | |
|
1705 Club Manor Drive,, Suite 2, Maumelle, AR 72113-7401 | |
| (501) 851-7402 | |
| (501) 851-4753 |
| Full Name | Dr Timothy John Dietrich |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 11 Years |
| Location | 1705 Club Manor Drive,, Maumelle, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053654608 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | E-3259 (Arkansas) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Medical Center-little Rock | Little rock, AR | Hospital |
| Baptist Health Medical Center-stuttgart | Stuttgart, AR | Hospital |
| Baptist Health Medical Center Heber Spings | Heber springs, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Arkansas Health Group | 7911802079 | 541 |
News Archive
The American Society for Biochemistry and Molecular Biology has named Jeremy M. Berg, director of the National Institute of General Medical Sciences, the winner of the nonprofit's 2011 ASBMB Howard K. Schachman Public Service Award. Berg will receive the award this evening at an ASBMB Public Affairs Advisory Committee meeting in Arlington, Va.
Medicare cut payments to 2,583 hospitals Tuesday, continuing the Affordable Care Act's eight-year campaign to financially pressure hospitals into reducing the number of patients who return for a second stay within a month.
NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.
A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defense. They have been able to prove that imiquimod transforms plasmacytoid dendritic cells (pDCs) into "tumour-killers" which can fight the tumour independently from other immune cells. This discovery could be an important step on the way to a more efficient treatment for cancer.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 8 days ago
| Entity Name | Baptist Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578593067 PECOS PAC ID: 0648177949 Enrollment ID: O20031215000977 |
News Archive
The American Society for Biochemistry and Molecular Biology has named Jeremy M. Berg, director of the National Institute of General Medical Sciences, the winner of the nonprofit's 2011 ASBMB Howard K. Schachman Public Service Award. Berg will receive the award this evening at an ASBMB Public Affairs Advisory Committee meeting in Arlington, Va.
Medicare cut payments to 2,583 hospitals Tuesday, continuing the Affordable Care Act's eight-year campaign to financially pressure hospitals into reducing the number of patients who return for a second stay within a month.
NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.
A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defense. They have been able to prove that imiquimod transforms plasmacytoid dendritic cells (pDCs) into "tumour-killers" which can fight the tumour independently from other immune cells. This discovery could be an important step on the way to a more efficient treatment for cancer.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 8 days ago
| Entity Name | Arkansas Health Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932118890 PECOS PAC ID: 7911802079 Enrollment ID: O20040726000650 |
News Archive
The American Society for Biochemistry and Molecular Biology has named Jeremy M. Berg, director of the National Institute of General Medical Sciences, the winner of the nonprofit's 2011 ASBMB Howard K. Schachman Public Service Award. Berg will receive the award this evening at an ASBMB Public Affairs Advisory Committee meeting in Arlington, Va.
Medicare cut payments to 2,583 hospitals Tuesday, continuing the Affordable Care Act's eight-year campaign to financially pressure hospitals into reducing the number of patients who return for a second stay within a month.
NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.
A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defense. They have been able to prove that imiquimod transforms plasmacytoid dendritic cells (pDCs) into "tumour-killers" which can fight the tumour independently from other immune cells. This discovery could be an important step on the way to a more efficient treatment for cancer.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Timothy John Dietrich, DO 1701 Club Manor Drive, , Suite 2, Maumelle, AR 72113-7401 Ph: (501) 851-7402 | Dr Timothy John Dietrich, DO 1705 Club Manor Drive,, Suite 2, Maumelle, AR 72113-7401 Ph: (501) 851-7402 |
News Archive
The American Society for Biochemistry and Molecular Biology has named Jeremy M. Berg, director of the National Institute of General Medical Sciences, the winner of the nonprofit's 2011 ASBMB Howard K. Schachman Public Service Award. Berg will receive the award this evening at an ASBMB Public Affairs Advisory Committee meeting in Arlington, Va.
Medicare cut payments to 2,583 hospitals Tuesday, continuing the Affordable Care Act's eight-year campaign to financially pressure hospitals into reducing the number of patients who return for a second stay within a month.
NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.
A research team from the Institute for Cancer Research at the MedUni Vienna has decoded a previously unknown mechanism of the active ingredient imiquimod in tumour defense. They have been able to prove that imiquimod transforms plasmacytoid dendritic cells (pDCs) into "tumour-killers" which can fight the tumour independently from other immune cells. This discovery could be an important step on the way to a more efficient treatment for cancer.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 8 days ago
Shamna Mohammed, M D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 Club Manor Dr Ste 2b, Maumelle, AR 72113 Phone: 501-851-7402 Fax: 501-851-4753 | |
Dr. Terence Benjamin Wilson, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 7 Norfork Cv, Maumelle, AR 72113 Phone: 501-803-0361 | |
Anna Szwedo, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 Club Manor Dr Ste 2b, Maumelle, AR 72113 Phone: 501-851-7400 | |
Dr. Hani Jamal Alturkmani, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 Club Manor Dr Ste 2b, Maumelle, AR 72113 Phone: 501-851-7402 Fax: 501-851-4753 | |
Muhammad Ressam Nazir, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 Club Manor Dr Ste 2b, Maumelle, AR 72113 Phone: 501-851-7402 Fax: 501-851-4753 | |
Lovepreet Singh, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1701 Club Manor Dr Ste 2b, Maumelle, AR 72113 Phone: 501-851-7402 Fax: 501-851-4753 |